Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$61.25
-0.4%		$63.26
$42.52
▼
$68.64
$125.13B0.1912.05 million shs3.24 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$64.89
+0.6%		$58.19
$36.00
▼
$65.59
$16.07B0.472.58 million shs880,822 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%+3.16%-2.01%-1.57%+40.45%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+3.70%+10.95%+15.62%+66.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$61.25
-0.4%		$63.26
$42.52
▼
$68.64
$125.13B0.1912.05 million shs3.24 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$64.89
+0.6%		$58.19
$36.00
▼
$65.59
$16.07B0.472.58 million shs880,822 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%+3.16%-2.01%-1.57%+40.45%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+3.70%+10.95%+15.62%+66.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.47
Hold$65.506.84% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$51.50-20.77% Downside

Current Analyst Ratings Breakdown

Latest BMY and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/26/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$82.00 ➝ $78.00
10/22/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
10/19/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSector Perform
10/19/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
10/19/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetMarket Outperform$55.00 ➝ $65.00
10/16/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
10/13/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform
10/13/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetEqual Weight$65.00 ➝ $60.00
10/12/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$76.00
10/12/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform
10/9/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Perform$45.00 ➝ $51.00
(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.60$8.11 per share7.56$9.09 per share6.74
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.94$3.05 per share21.32$8.06 per share8.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5413.509.430.3118.87%66.90%14.74%10/29/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1820.4417.521.8135.33%42.17%31.76%10/29/2026 (Estimated)

Latest BMY and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.10N/AN/AN/A$12.73 billionN/A
10/29/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8870N/AN/AN/A$646.51 millionN/A
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.11%+1.61%55.51%17 Years
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A

Latest BMY and EXEL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/15/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.12%10/2/202610/2/202611/2/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable

Recent News About These Companies

Laboratory bench with pipettes, microplates, a centrifuge, analytical balance, and chromatography equipment.
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock (EXEL)
...
 |  marketbeat.comhttps://www.marketbeat.com/articles/bristol-myers-squibbs-cancer-breakthrough-could-have-implications-beyond-its-own-stock/
Exelixis (NASDAQ:EXEL) Hits New 12-Month High - What's Next?
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-exelixis-nasdaq-exel-hits-new-12-month-high-whats-next-2026-10-26/
40,650 Exelixis, Inc. $EXEL Shares Purchased by Sterling Capital Management LLC
October 26 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-40650-exelixis-inc-exel-shares-purchased-by-sterling-capital-management-llc-2026-10-26/
Exelixis, Inc. $EXEL Shares Sold by EULAV Asset Management
October 26 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-sold-by-eulav-asset-management-2026-10-26/
RBC raises target for Exelixis stock from USD 45 to USD 51
October 24 at 7:38 PM  |  ad-hoc-news.deA
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
October 24 at 7:30 PM  |  fool.comhttps://www.fool.com/investing/2026/10/24/forget-the-fda-delay-3-reasons-exelixis-is-still-a/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=0fa60f5b-17e9-4f3f-b47f-1afd0e334896
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
October 24 at 7:00 PM  |  fool.comhttps://www.fool.com/investing/2026/10/24/forget-the-fda-delay-3-reasons-exelixis-is-still-a/
Exelixis, Inc. $EXEL Stock: Nisa Investment Advisors LLC Grows Stake
October 24 at 9:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-stock-nisa-investment-advisors-llc-grows-stake-2026-10-24/
Exelixis (NASDAQ:EXEL) Stock Bumped Up to Strong-Buy by Wall Street Zen
October 24 at 4:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-exelixis-nasdaq-exel-stock-bumped-up-to-strong-buy-by-wall-street-zen-2026-10-24/
Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run
October 23 at 2:34 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/exelixis-exel-stock-may-bargain-091248602.html
Exelixis Rises with Earnings on Tap
October 23 at 9:00 AM  |  fxempire.comF
207,444 Exelixis, Inc. $EXEL Shares Sold by Robeco Institutional Asset Management B.V.
October 23 at 4:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-207444-exelixis-inc-exel-shares-sold-by-robeco-institutional-asset-management-bv-2026-10-23/
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
October 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3012937/exelixis-exel-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-3012937
Exelixis (EXEL) Set to Release Earnings on Thursday
October 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-exelixis-exel-set-to-release-earnings-on-thursday-2026-10-22/
Exelixis, Inc. (EXEL) - What Are Analysts Saying About This Stock?
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31144893
Exelixis (NASDAQ:EXEL) Sets New 12-Month High Following Analyst Upgrade
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31144649
Citizens lifts target to USD 65 for Exelixis stock
October 21, 2026  |  ad-hoc-news.deA
Exelixis, Inc. $EXEL Stock Sold by Assenagon Asset Management S.A.
October 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-stock-sold-by-assenagon-asset-management-sa-2026-10-21/
Exelixis (NASDAQ:EXEL) Sets New 52-Week High After Analyst Upgrade
October 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-exelixis-nasdaq-exel-sets-new-52-week-high-after-analyst-upgrade-2026-10-20/
Exelixis, Inc. $EXEL Position Boosted by IFP Advisors Inc
October 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-position-boosted-by-ifp-advisors-inc-2026-10-20/
Exelixis (EXEL) PT Raised to $65 at Citizens Ahead of ESMO '26
October 19, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Exelixis+%28EXEL%29+PT+Raised+to+%2465+at+Citizens+Ahead+of+ESMO+26/27199732.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated Nike swoosh logo on a wall above a display pedestal with sneakers in a retail store.
Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
By Thomas Hughes | October 4, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
Close-up of an Nvidia logo on a computer chip mounted on a circuit board with cables and hardware components.
NVIDIA Just Strengthened the Case for Its Massive Stock Price Upside
By Thomas Hughes | September 29, 2026
Television displaying the Netflix logo in a dark living room with a coffee table, popcorn bowl, and remote.
Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
By Sam Quirke | September 30, 2026
Laboratory bench with pipettes, microplates, a centrifuge, analytical balance, and chromatography equipment.
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
By Nathan Reiff | October 26, 2026
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$61.24 -0.24 (-0.38%)
As of 03:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$64.89 +0.36 (+0.55%)
As of 03:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas